↓ Skip to main content

Current management and novel agents for malignant melanoma

Overview of attention for article published in Journal of Hematology & Oncology, February 2012
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (74th percentile)

Mentioned by

twitter
1 X user
patent
1 patent

Citations

dimensions_citation
39 Dimensions

Readers on

mendeley
71 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Current management and novel agents for malignant melanoma
Published in
Journal of Hematology & Oncology, February 2012
DOI 10.1186/1756-8722-5-3
Pubmed ID
Authors

Byung Lee, Nikhil Mukhi, Delong Liu

Abstract

Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alpha-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF V600E mutation, and ipilimumab for treatment of unresectable or metastatic melanoma. This review will also update on the development of novel agents, including tyrosine kinase inhibitors and adoptive cellular therapy.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 71 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 15 21%
Student > Ph. D. Student 9 13%
Researcher 9 13%
Student > Postgraduate 9 13%
Student > Doctoral Student 7 10%
Other 12 17%
Unknown 10 14%
Readers by discipline Count As %
Medicine and Dentistry 22 31%
Agricultural and Biological Sciences 22 31%
Biochemistry, Genetics and Molecular Biology 5 7%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Immunology and Microbiology 2 3%
Other 4 6%
Unknown 12 17%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 May 2021.
All research outputs
#6,378,576
of 22,663,150 outputs
Outputs from Journal of Hematology & Oncology
#438
of 1,187 outputs
Outputs of similar age
#59,471
of 250,850 outputs
Outputs of similar age from Journal of Hematology & Oncology
#3
of 4 outputs
Altmetric has tracked 22,663,150 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 1,187 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 250,850 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.